Author: Bret Jensen, Biotech Gems

This Stock is a Major Position in My Portfolio

The company sports gross margins north of 80%, its balance sheet is pristine with no net debt, it invests heavily in R&D, over the next five years it should throw off $50-$70 billion in free cash flow, it initiated its first dividend this year, and it has a $15 billion stock buyback program in place. On top of all of this, earnings are growing and shares sell for less than nine times this year’s profits…

Read More